Voyager Therapeutics, Inc. (VYGR) Presents at Wells Fargo 21st Annual Healthcare Conference Transcri

BlackRock Inc. acquired a new position in shares of Voyager Therapeutics, Inc. (NASDAQ: VYGR) in the

LEXINGTON, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a bi

Dimensional Fund Advisors LP decreased its position in Voyager Therapeutics, Inc. (NASDAQ: VYGR) by

HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Voyager Therapeutics (NASDAQ:VYGR)

Voyager Therapeutics (NASDAQ:VYGR) reported quarterly losses of $(0.40) per share which beat the ana

- Data presented as Developing Topics poster at AAIC 2026 -LEXINGTON, Mass., July 13, 2026 (GLOBE NE

- Data presented as Developing Topics poster at AAIC 2026 - LEXINGTON, Mass., July 13, 2026 (GLOBE N

On the June 30 episode of Mad Money, a 23-year-old caller named Jackson from Iowa asked Jim Cramer a

Jim Cramer recommended buying GE Vernova Inc. as Bernstein analyst initiated coverage with an Outper

LEXINGTON, Mass. , June 29, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a bi

Voyager Technologies Chairman and CEO Dylan Taylor joins ‘Mornings with Maria' to discuss SpaceX's r

LEXINGTON, Mass., June 11, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a bio

Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics

- Dosing of adults with early Alzheimer's disease in clinical trial expected H2 2026 - - Comprehensi

- VY1706 IND application process on track for Q2 2026; clinical entry expected H2 2026 - - Data from

Voyager Therapeutics (VYGR) came out with a quarterly loss of $0.47 per share versus the Zacks Conse

Voyager Therapeutics (NASDAQ:VYGR) reported quarterly losses of $(0.47) per share which beat the ana

- VY1706 and NBIB-‘233 completed IND-enabling GLP toxicology; clinical entry expected H2 2026 - - Mu

- Late-breaking oral presentation: IV delivery of VY1706, a CNS penetrant AAV gene therapy for AD, d

- Late-breaking oral presentation: IV delivery of VY1706, a CNS penetrant AAV gene therapy for AD, d

https://www.sec.gov/ix?doc=/Archives/edgar/data/1640266/000110465926045997/tm2612325d1_8k.htm

Longeveron (NASDAQ: LGVN - Get Free Report) and Voyager Therapeutics (NASDAQ: VYGR - Get Free Report

Voyager Therapeutics maintains a "Strong Buy" rating as it approaches a pivotal 2026 catalyst with t

Voyager Therapeutics, Inc. (VYGR) Presents at Stifel 2026 Virtual CNS Forum Transcript

HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Voyager Therapeutics (NASDAQ:VYGR)

Voyager Therapeutics (VYGR) came out with a quarterly loss of $0.46 per share versus the Zacks Conse

Voyager Therapeutics (NASDAQ:VYGR) reported quarterly losses of $(0.46) per share which beat the ana

- Transformative year for tau in AD: VY1706 clinical entry and VY7523 clinical data anticipated H2 2

Johnson & Johnson ends its Phase 2b posdinemab trial after missing key Alzheimer's goals, ra

HC Wainwright & Co. analyst Patrick R. Trucchio maintains Voyager Therapeutics (NASDAQ:VYGR)

Voyager Therapeutics (NASDAQ:VYGR) reported quarterly losses of $(0.47) per share which beat the ana

Voyager's Alzheimer's programs show longer CNS exposure and potential gene therapy advances,

HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Voyager Therapeutics (NASDAQ:VYGR)

Wedbush analyst Yun Zhong maintains Voyager Therapeutics (NASDAQ:VYGR) with a Outperform and lowe

Voyager Therapeutics (NASDAQ:VYGR) reported quarterly losses of $(0.57) per share which missed the a

New program combines IV-delivered TRACER capsid with bifunctional payload to silence APOE in carrier

Voyager Therapeutics, Inc. (NASDAQ:VYGR), a biotechnology company dedicated to leveraging genetics t

Voyager Therapeutics (NASDAQ:VYGR) reported quarterly losses of $(0.53) per share which missed the a

HC Wainwright & Co. analyst Patrick Trucchio reiterates Voyager Therapeutics (NASDAQ:VYGR) wi

- Single IV administration of tau silencing gene therapy VY1706 significantly reduced tau mRNA and p

Canaccord Genuity analyst Sumant Kulkarni maintains Voyager Therapeutics (NASDAQ:VYGR) with a Buy

HC Wainwright & Co. analyst Patrick Trucchio reiterates Voyager Therapeutics (NASDAQ:VYGR) wi

Wells Fargo analyst Yanan Zhu maintains Voyager Therapeutics (NASDAQ:VYGR) with a Overweight and